vs
Side-by-side financial comparison of Gain Therapeutics, Inc. (GANX) and Intellia Therapeutics, Inc. (NTLA), based on the latest 10-Q / 10-K filings. Click either name above to swap in a different company.
Intellia Therapeutics, Inc. is the larger business by last-quarter revenue ($23.0M vs $105.4K, roughly 218.4× Gain Therapeutics, Inc.). Intellia Therapeutics, Inc. runs the higher net margin — -4255.7% vs -416.2%, a 3839.5% gap on every dollar of revenue. Gain Therapeutics, Inc. produced more free cash flow last quarter ($-6.1M vs $-69.4M).
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
GANX vs NTLA — Head-to-Head
Income Statement — Q3 2024 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $105.4K | $23.0M |
| Net Profit | $-4.5M | $-95.8M |
| Gross Margin | — | — |
| Operating Margin | -4230.3% | -428.9% |
| Net Margin | -4255.7% | -416.2% |
| Revenue YoY | — | 78.8% |
| Net Profit YoY | 4.9% | 25.7% |
| EPS (diluted) | $-0.17 | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align — see 8-quarter trend below.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history — bar widths are scaled to the larger of the two companies so you can eyeball the size gap and growth trajectory without doing math. Quarters aligned by calendar period (report date) so offset fiscal years line up.
| Q4 25 | — | $23.0M | ||
| Q3 25 | — | $13.8M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.6M | ||
| Q4 24 | — | $12.9M | ||
| Q3 24 | $105.4K | $9.1M | ||
| Q2 24 | $84.5K | $7.0M | ||
| Q1 24 | $115.3K | $28.9M |
| Q4 25 | — | $-95.8M | ||
| Q3 25 | — | $-101.3M | ||
| Q2 25 | — | $-101.3M | ||
| Q1 25 | — | $-114.3M | ||
| Q4 24 | — | $-128.9M | ||
| Q3 24 | $-4.5M | $-135.7M | ||
| Q2 24 | $-8.1M | $-147.0M | ||
| Q1 24 | $-4.0M | $-107.4M |
| Q4 25 | — | -428.9% | ||
| Q3 25 | — | -808.9% | ||
| Q2 25 | — | -772.2% | ||
| Q1 25 | — | -726.6% | ||
| Q4 24 | — | -1059.9% | ||
| Q3 24 | -4230.3% | -1589.0% | ||
| Q2 24 | -9680.3% | -1998.6% | ||
| Q1 24 | -3796.7% | -394.0% |
| Q4 25 | — | -416.2% | ||
| Q3 25 | — | -735.2% | ||
| Q2 25 | — | -710.8% | ||
| Q1 25 | — | -687.6% | ||
| Q4 24 | — | -1001.2% | ||
| Q3 24 | -4255.7% | -1489.5% | ||
| Q2 24 | -9633.2% | -2112.6% | ||
| Q1 24 | -3481.4% | -371.3% |
| Q4 25 | — | $-0.81 | ||
| Q3 25 | — | $-0.92 | ||
| Q2 25 | — | $-0.98 | ||
| Q1 25 | — | $-1.10 | ||
| Q4 24 | — | $-1.27 | ||
| Q3 24 | $-0.17 | $-1.34 | ||
| Q2 24 | $-0.42 | $-1.52 | ||
| Q1 24 | $-0.22 | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest filing — the kind of financial-strength check premium terminals charge for.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $12.0M | $449.9M |
| Total DebtLower is stronger | $494.4K | — |
| Stockholders' EquityBook value | $8.9M | $671.4M |
| Total Assets | $14.4M | $842.1M |
| Debt / EquityLower = less leverage | 0.06× | — |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q4 25 | — | $449.9M | ||
| Q3 25 | — | $511.0M | ||
| Q2 25 | — | $459.7M | ||
| Q1 25 | — | $503.7M | ||
| Q4 24 | — | $601.5M | ||
| Q3 24 | $12.0M | $658.1M | ||
| Q2 24 | $16.9M | $691.1M | ||
| Q1 24 | $12.7M | $791.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $494.4K | — | ||
| Q2 24 | $486.4K | — | ||
| Q1 24 | $507.7K | — |
| Q4 25 | — | $671.4M | ||
| Q3 25 | — | $748.4M | ||
| Q2 25 | — | $715.3M | ||
| Q1 25 | — | $779.9M | ||
| Q4 24 | — | $872.0M | ||
| Q3 24 | $8.9M | $962.6M | ||
| Q2 24 | $11.8M | $971.1M | ||
| Q1 24 | $8.6M | $1.0B |
| Q4 25 | — | $842.1M | ||
| Q3 25 | — | $925.3M | ||
| Q2 25 | — | $898.9M | ||
| Q1 25 | — | $986.2M | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | $14.4M | $1.2B | ||
| Q2 24 | $19.2M | $1.2B | ||
| Q1 24 | $14.6M | $1.3B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.06× | — | ||
| Q2 24 | 0.04× | — | ||
| Q1 24 | 0.06× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Net income can be massaged; cash flow is harder to fake.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.1M | $-69.3M |
| Free Cash FlowOCF − Capex | $-6.1M | $-69.4M |
| FCF MarginFCF / Revenue | -5764.6% | -301.6% |
| Capex IntensityCapex / Revenue; lower = less reinvestment burden | 0.0% | 0.5% |
| Cash ConversionOCF / Net Profit; >1× = earnings back up with cash | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-395.9M |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q4 25 | — | $-69.3M | ||
| Q3 25 | — | $-76.9M | ||
| Q2 25 | — | $-99.6M | ||
| Q1 25 | — | $-148.9M | ||
| Q4 24 | — | $-85.2M | ||
| Q3 24 | $-6.1M | $-84.8M | ||
| Q2 24 | $-5.8M | $-58.2M | ||
| Q1 24 | $-3.6M | $-120.7M |
| Q4 25 | — | $-69.4M | ||
| Q3 25 | — | $-76.9M | ||
| Q2 25 | — | $-99.9M | ||
| Q1 25 | — | $-149.7M | ||
| Q4 24 | — | $-86.2M | ||
| Q3 24 | $-6.1M | $-86.1M | ||
| Q2 24 | — | $-59.2M | ||
| Q1 24 | — | $-123.2M |
| Q4 25 | — | -301.6% | ||
| Q3 25 | — | -558.2% | ||
| Q2 25 | — | -701.0% | ||
| Q1 25 | — | -900.1% | ||
| Q4 24 | — | -669.4% | ||
| Q3 24 | -5764.6% | -945.2% | ||
| Q2 24 | — | -850.9% | ||
| Q1 24 | — | -425.7% |
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 4.4% | ||
| Q4 24 | — | 7.6% | ||
| Q3 24 | 0.0% | 14.0% | ||
| Q2 24 | — | 14.5% | ||
| Q1 24 | — | 8.7% |
Financial Flow Comparison
Sankey diagram of revenue → gross profit → operating profit → net profit for each company. Charts shown full-width and stacked so both segment hierarchies are readable side-by-side on desktop and mobile.
Revenue Breakdown by Segment
GANX
Segment breakdown not available.
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
